荷兰钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）的健康和预算影响

数据集获取（Figshare）

• 源站标题：The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands
• DOI：10.6084/m9.figshare.22352863.v2
• 发布日期：2023-04-13
• 文件数：1 个
• 文件总体积：13.17 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/The_health_and_budget_impact_of_sodium-glucose_co-transporter-2_inhibitors_SGLT2is_in_the_Netherlands/22352863

命令行下载

curl -L -o "ijme_a_2194802_sm0663.xlsx" "https://ndownloader.figshare.com/files/39772378"

文件清单

• ijme_a_2194802_sm0663.xlsx（13.17 KB）

文件总体积 13.17 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Type-2 Diabetes mellitus (T2DM) increases both the patient risk of cardiovascular disease (CVD) and renal outcomes, such as chronic kidney disease (CKD). Recent clinical trials of the glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is) have shown benefits in preventing CVD events and progression of CKD, leading to an update of the Dutch T2DM treatment guideline for patients at risk. The aim of this study is to assess the health and economic impact of the guideline-recommended utilization of SGLT2is in the Netherlands.
The patient population at risk was determined by multiplying Dutch T2DM prevalence rates with the total numbers of inhabitants of the Netherlands in 2020. Subsequently, two analyses, comparing a treatment setting before and after implementation of the new guideline for SGLT2is, were conducted. Clinical and adverse event rates in both settings as well as direct healthcare costs were sourced from the literature. Total costs were calculated by multiplying disease prevalence, event rates and costs associated to outcomes. One-time disutilities per event were included to estimate the health impact. The potential health and economic impact of implementing the updated guideline was calculated.
Using a 5-year time horizon, the guideline-suggested utilization of SGLT2is resulted in a health impact equal to 4835 quality adjusted life years gained (0.0031 per patient per year) and €461 million cost-savings. The costs of treatment with SGLT2is were €813 million. Hence the net budget impact was €352 million for the total Dutch T2DM population, which translated to €0,57 per patient per day.
SGLT2is offer an option to reduce the number of CVD and CKD related events and associated healthcare costs and health losses in the Netherlands. Further research is needed to include the benefits of improved T2DM management options from a broader societal perspective.Highlights
The glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is) has shown benefits in preventing cardiovascular events and progression of kidney disease in patients with type-2 diabetes leading to a revision of the respective Dutch treatment gui

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.22352863.v2（source: https://tandf.figshare.com/articles/dataset/The_health_and_budget_impact_of_sodium-glucose_co-transporter-2_inhibitors_SGLT2is_in_the_Netherlands/22352863）。